These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 30332697)

  • 1. Apixaban for Treating Venous Thromboembolism in Real-World Clinical Practice.
    Monreal M
    Thromb Haemost; 2018 Nov; 118(11):1850-1851. PubMed ID: 30332697
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study.
    Sindet-Pedersen C; Staerk L; Pallisgaard JL; Gerds TA; Berger JS; Torp-Pedersen C; Gislason GH; Olesen JB
    Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):220-227. PubMed ID: 29945162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study.
    Ageno W; Vedovati MC; Cohen A; Huisman M; Bauersachs R; Gussoni G; Becattini C; Agnelli G
    Thromb Haemost; 2021 May; 121(5):616-624. PubMed ID: 33202447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apixaban for extended treatment of venous thromboembolism.
    Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Porcari A; Raskob GE; Weitz JI;
    N Engl J Med; 2013 Feb; 368(8):699-708. PubMed ID: 23216615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of factor Xa inhibitors in venous thromboembolism treatment.
    Cabral KP; Ansell JE
    Vasc Health Risk Manag; 2015; 11():117-23. PubMed ID: 25673997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Treatment of Venous Thromboembolism in the Elderly.
    Boey JP; Gallus A
    Drugs Aging; 2016 Jul; 33(7):475-90. PubMed ID: 27255713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
    Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
    Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
    McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
    Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical use of apixaban in the prevention of venous thromboembolism after total knee or hip replacement.
    Lassen MR
    Drugs Today (Barc); 2012 Apr; 48(4):249-58. PubMed ID: 22536567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis.
    King DA; Pow RE; Dickison DM; Vale PR
    Intern Med J; 2016 Sep; 46(9):1030-7. PubMed ID: 27246450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apixaban (Eliquis) in deep vein thrombosis and pulmonary embolism. Warfarin remains the standard therapy.
    Prescrire Int; 2015 Sep; 24(163):206. PubMed ID: 26417627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apixaban versus enoxaparin in elective major orthopedic surgery: a clinical review.
    Maniscalco P; Caforio M; Imberti D; Porcellini G; Benedetti R
    Clin Appl Thromb Hemost; 2015 Mar; 21(2):115-9. PubMed ID: 25125051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study).
    Nakamura M; Nishikawa M; Komuro I; Kitajima I; Uetsuka Y; Yamagami T; Minamiguchi H; Yoshimatsu R; Tanabe K; Matsuoka N; Kanmuri K; Ogawa H
    Circ J; 2015; 79(6):1230-6. PubMed ID: 25912695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are apixaban and rivaroxaban distributed into human breast milk to clinically relevant concentrations?
    Zhao Y; Arya R; Couchman L; Patel JP
    Blood; 2020 Oct; 136(15):1783-1785. PubMed ID: 32488251
    [No Abstract]   [Full Text] [Related]  

  • 15. Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials.
    Beyer-Westendorf J; Lensing AW; Arya R; Bounameaux H; Cohen AT; Wells PS; Middeldorp S; Verhamme P; Hughes R; Kucher N; Pap AF; Trajanovic M; Prins MH; Prandoni P; Weitz JI
    Thromb Res; 2017 Jan; 149():29-37. PubMed ID: 27886530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics, pharmacokinetics and clinical efficacy of apixaban in the treatment of thrombosis.
    Zheng SS; Chong JJ; Chong BH
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):575-80. PubMed ID: 26982962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.
    Carrier M; Abou-Nassar K; Mallick R; Tagalakis V; Shivakumar S; Schattner A; Kuruvilla P; Hill D; Spadafora S; Marquis K; Trinkaus M; Tomiak A; Lee AYY; Gross PL; Lazo-Langner A; El-Maraghi R; Goss G; Le Gal G; Stewart D; Ramsay T; Rodger M; Witham D; Wells PS;
    N Engl J Med; 2019 Feb; 380(8):711-719. PubMed ID: 30511879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Would apixaban be a good option for extended anticoagulation in venous thromboembolism?
    Wu MA; Cernuschi G
    Intern Emerg Med; 2014 Feb; 9(1):99-100. PubMed ID: 23857037
    [No Abstract]   [Full Text] [Related]  

  • 19. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
    Cornell RF; Goldhaber SZ; Engelhardt BG; Moslehi J; Jagasia M; Harrell S; Rubinstein SM; Hall R; Wyatt H; Piazza G
    Br J Haematol; 2020 Aug; 190(4):555-561. PubMed ID: 32314352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Proper use of apixaban: an outline for clinical practice].
    Albaladejo P; Deplanque D; Fossati F; Mahagne MH; Mismetti P; Nguyen P; Roy P; Touze E; Mourad JJ
    J Mal Vasc; 2014 Dec; 39(6):409-25. PubMed ID: 25451020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.